- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07946757
Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Minghui Li, Ph.D
- 전화번호: 010-84322284
- 이메일: Wuhm2000@sina.com
연구 장소
-
-
-
Beijing, 중국
- Beijing Ditan Hospital, Capital Medical University
-
연락하다:
- Minghui Li
-
Xi'an, 중국
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
연락하다:
- Shuangsuo Dang
-
Xiamen, 중국
- The First Affiliated Hospital of Xiamen University
-
연락하다:
- Xiulan Xue
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Voluntarily participate in this trial and sign the informed consent form;
- Aged 18 to 65 years (inclusive), male or female;
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.
Exclusion Criteria:
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
- History of other liver diseases;
- History of liver cirrhosis;
- Imaging suggestive of a suspected malignant hepatic lesion;
- Past or current evidence of hepatic decompensation;
- History of extrahepatic diseases potentially associated with HBV immune status;
- Other diseases associated with vasculitis;
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
- History of malignancy;
- Prior solid organ or bone marrow transplantation;
- Presence or history of severe psychiatric disorders;
- Severe retinopathy or other serious ophthalmic diseases;
- Prior or current use of prohibited medications;
- Concomitant hematological diseases;
- Abnormal laboratory findings;
- Abnormal QTcF interval;
- History of allergy;
- Lactating female subjects or those with a positive serum pregnancy test at screening;
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 그룹 2
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
실험적: 그룹 1
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
실험적: 그룹 3
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
실험적: 그룹 4
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
기간: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
HBsAg, HBsAb and HBV DNA levels and changes from baseline
기간: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroclearance rate
기간: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroconversion rate
기간: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Minghui Li, Ph.D, Beijing Ditan Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- ACT201-4-1-002
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .